Abundant glutamic acid decarboxylase (GAD)-reactive B cells in gad-antibody-associated neurological disorders.


Journal

Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449

Informations de publication

Date de publication:
03 2019
Historique:
received: 18 07 2018
revised: 09 01 2019
accepted: 09 01 2019
pubmed: 13 1 2019
medline: 14 1 2020
entrez: 13 1 2019
Statut: ppublish

Résumé

High levels of antibodies against glutamic acid decarboxylase (GAD) are observed in patients with different neurological disorders, but cells producing these autoantibodies are largely unexplored. We detect circulating GAD-reactive B cells in peripheral blood that readily differentiate into antibody-producing cells. These cells are highly elevated in most patients with GAD-antibody-associated disorders (n = 15) compared to controls (n = 19). They mainly produce GAD65 antibodies of the IgG1 and IgG4 subclasses and are as abundant as B cells reactive for common recall antigens. Bone marrow cells represent an additional source of GAD antibodies. The identification of GAD-antibody-producing cells has implications for the selection of cell-specific biologics. ANN NEUROL 2019;85:448-454.

Identifiants

pubmed: 30635933
doi: 10.1002/ana.25414
doi:

Substances chimiques

Autoantibodies 0
Immunoglobulin G 0
Glutamate Decarboxylase EC 4.1.1.15
glutamate decarboxylase 1 EC 4.1.1.15
glutamate decarboxylase 2 EC 4.1.1.15

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

448-454

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : SFB TR128
Pays : International
Organisme : Kompetenznetz Degenerative Demenzen
Pays : International
Organisme : Krankheitsbezogenes Kompetenznetz Multiple Sklerose
Pays : International
Organisme : Federal Ministry of Education and Research
Pays : International
Organisme : Munich Cluster for Systems Neurology
ID : ExC 1010 SyNergy
Pays : International

Informations de copyright

© 2019 American Neurological Association.

Auteurs

Franziska S Thaler (FS)

Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.

Anna L Thaller (AL)

Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.

Michelle Biljecki (M)

Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.

Elisabeth Schuh (E)

Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.

Stephan Winklmeier (S)

Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.

Christoph F Mahler (CF)

Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.

Ramona Gerhards (R)

Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.

Stefanie Völk (S)

Department of Neurology, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.

Frauke Schnorfeil (F)

Department of Medicine III, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.

Marion Subklewe (M)

Department of Medicine III, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.

Reinhard Hohlfeld (R)

Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Tania Kümpfel (T)

Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.

Edgar Meinl (E)

Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH